After signing an agreement for the creation of a mixed Algerian-French company, on December 7, 2017 in Paris, at the meeting in Matignon of the High Algerian-French Intergovernmental Committee, and in accordance with the 49/51 rule governing investment in Algeria, the pharmaceutical company Ipsen, which already has a liaison office in Algeria, and Isly Holding, a local investment company, organized today, at the International Conference Center in Algiers, a ceremony for the official launch of the first factory in Africa for the manufacture of a drug in oncology. This plant will produce DECAPEPTYL® 3.75mg and 11.25mg for the Algerian market.
Decapeptyl® is an injectable formulation of a decapeptide used primarily for the treatment of localized high-risk, locally advanced or metastatic prostate cancer. Subsequently, additional indications included the treatment of uterine fibroids (benign tumor of muscle tissue of the uterus), endometriosis (proliferation of endometrial tissue outside the uterine cavity from stage I to stage IV), and than the treatment of central precocious puberty and female infertility. Ipsen and Isly will also produce long-acting peptide forms with specific and complex methods.
On this occasion, Mr. Adlane Soudani, CEO of Ipsen Pharma in Algeria said he was very happy “to launch this investment program in Algeria for the manufacture of complex drugs intended to treat serious pathologies responding to strong medical needs of Algerian patients. For his part, Mr. Lyes Boudiaf, founder and President of Isly Holding, said that “this partnership is a new step confirming the development of Isly Holding’s activities, in the continuity of my activities for several years in different sectors related to industry “. Mr. Boudiaf especially emphasized his determination “to help meet the expectations of the Algerian authorities regarding the development of local industry”.
As a reminder, this oncology drug factory is an investment that ranges from 20 to 25 million euros and will create 150 direct jobs. It will cover, according to its promoters, all local demand and will generate an export surplus for sub-Saharan Africa.